Defy Medical Company Overview & Business Model: An Independent Clinical Assessment

What Is Defy Medical and How Does It Operate?

Defy Medical is a U.S. Telehealth practice that focuses on hormonal health, TRT, peptides, and what its providers call "longevity medicine." The practice does not accept insurance. Patients pay cash for each service, which gives the clinical team flexibility to prescribe outside the narrow formularies that insurance plans typically approve.

Founding and Clinical Structure

The practice opened in 2012, well before most direct-to-consumer TRT companies entered the market. Its medical director, Dr. Justin Saya, is a licensed physician whose clinical focus is hormone optimization. The practice employs nurse practitioners and physicians who conduct consultations via telemedicine video calls, then coordinate lab draws through third-party labs (LabCorp and Quest are commonly used by patients, though Defy has also offered in-house lab panels).

Unlike subscription-only TRT startups that mail a single testosterone formulation to patients, Defy positions itself as a full clinical practice. Patients receive individualized protocols rather than standardized dosing packages.

The Cash-Pay Concierge Model Explained

Cash-pay concierge telehealth means patients bypass their insurance network entirely. The practical effect is significant. Insurance-contracted endocrinologists are generally bound by payer formularies that require serum testosterone to fall below 300 ng/dL before approving therapy, following older American Urological Association thresholds. AUA guidelines define hypogonadism as a total testosterone <300 ng/dL, though the Endocrine Society's 2018 Clinical Practice Guideline sets the threshold at <264 ng/dL before initiating therapy in symptomatic men.

Defy Medical's providers can evaluate symptoms alongside labs, and they may initiate treatment in patients who are symptomatic even when total testosterone sits in the low-normal range, a practice that remains debated in the literature but is not prohibited by law.

What Does Defy Medical Actually Prescribe?

The formulary is the clearest differentiator between Defy Medical and insurance-based endocrinology. The practice prescribes across several categories that most primary care physicians and most direct-to-consumer TRT startups do not offer.

Testosterone Replacement Therapy (TRT)

Defy prescribes multiple testosterone formulations, including:

• Testosterone cypionate (injectable, the most common protocol): typically 100 to 200 mg per week divided into twice-weekly subcutaneous or intramuscular doses.
• Testosterone enanthate: similar pharmacokinetics to cypionate, half-life roughly 4.5 days.
• Testosterone propionate: shorter half-life, less common, used for fine-tuning protocols.
• Compounded testosterone creams and gels: used for patients who prefer transdermal delivery or for female hormone protocols.
• Testosterone pellets: subdermal pellets placed every 3 to 6 months; Defy has offered this but it is less central to their model than injections.

Ancillary medications commonly prescribed alongside TRT at Defy include anastrozole (an aromatase inhibitor to control estradiol), human chorionic gonadotropin (hCG) to preserve testicular function, and enclomiphene or clomiphene citrate for patients who prefer to stimulate endogenous production.

The T Trials (N=790 symptomatic hypogonadal men aged 65+) published in the New England Journal of Medicine in 2016 demonstrated that testosterone treatment improved sexual function, physical capacity, and bone mineral density vs. Placebo, providing foundational evidence for the clinical rationale behind TRT practices like Defy.

Peptide Therapy

This is the area where Defy Medical most visibly diverges from standard-of-care practices. The clinic has prescribed growth hormone secretagogues including:

• Sermorelin: a GHRH analog that stimulates the pituitary to release growth hormone.
• Ipamorelin/CJC-1295: a combination commonly used for GH pulse amplification.
• BPC-157: a body-protective compound studied in animal models for tissue repair; preclinical data from Sikiric et al. Show gastroprotective and tendon-healing properties in rodents, though no Phase III human trials have been completed.
• PT-141 (bremelanotide): a melanocortin agonist; the FDA-approved version Vyleesi is indicated for hypoactive sexual desire disorder in premenopausal women, though Defy has prescribed compounded versions off-label.
• Thymosin beta-4 (TB-500): an actin-sequestering peptide studied for wound healing.

Patients should understand that most peptides beyond sermorelin and PT-141 (in its FDA-approved form) lack Phase III human clinical trial data. The FDA has taken enforcement action against certain compounded peptides, and the regulatory status of individual peptides changes periodically. Prescribing these compounds is legal through licensed physicians, but the evidence base varies widely by compound.

Female Hormone Therapy and Other Services

Defy also prescribes bioidentical hormone therapy for women, including estradiol and progesterone formulations, testosterone for female patients (off-label per FDA labeling but supported by The Menopause Society's 2022 position statement on testosterone therapy in women), thyroid optimization (including T3/T4 combination therapy and desiccated thyroid), and GLP-1 receptor agonists for weight management.

Is Defy Medical Legitimate? Licensing and Regulatory Standing

Defy Medical operates as a licensed medical practice in Florida and provides telemedicine services under individual state licensing requirements across the U.S. The practice is not a supplement company or wellness app. Prescriptions are issued by licensed physicians and nurse practitioners operating under standard state medical board oversight.

DEA Scheduling and Controlled Substance Compliance

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Defy Medical providers must hold DEA registration to prescribe testosterone, and they are subject to the same prescribing audit risk as any other licensed prescriber. Patients should verify their state's telemedicine prescribing rules, as interstate prescribing of Schedule III substances carries specific requirements.

Compounding Pharmacy Partners

Defy Medical historically has worked with 503A and 503B compounding pharmacies to fulfill prescriptions. The FDA distinguishes 503A pharmacies (patient-specific, require a valid prescription) from 503B outsourcing facilities (can produce larger batches, subject to cGMP standards). Using licensed compounding pharmacies for testosterone and hormone preparations is legal and common across U.S. Hormone practices.

No public FDA warning letters naming Defy Medical as a respondent appear in the FDA's publicly searchable database as of the date of this review. That absence does not guarantee future regulatory status, and patients should monitor for any changes.

How Much Does Defy Medical Cost?

Cost is one of the most frequently asked questions about Defy Medical, and the answer requires breaking the total cost into components, because no single number captures the full picture.

Consultation Fees

Initial consultations at Defy Medical have been priced at approximately $250, $350. Follow-up consultations are typically less expensive, ranging from $100, $175 depending on complexity and provider type (physician vs. Nurse practitioner). These figures are based on patient-reported data and are subject to change; always verify current pricing directly with the practice.

Laboratory Costs

Defy Medical orders lab panels that are more comprehensive than what most primary care physicians order. A standard male TRT panel may include total testosterone, free testosterone (calculated or direct), SHBG, LH, FSH, estradiol (sensitive assay), CBC, CMP, PSA (for men over 40), and a lipid panel. At commercial labs, this panel can cost $150, $400 without insurance.

Medication Costs

Compounded testosterone cypionate from a partner pharmacy typically costs $30, $80 per month depending on dose and pharmacy. Ancillary medications add cost: anastrozole is inexpensive generically ($10, $30/month), while peptide protocols can add $150, $400/month or more depending on the specific compounds.

Total Annual Cost Estimate

A realistic annual cost for a male TRT patient at Defy Medical with quarterly follow-ups, two lab panels per year, and a basic testosterone/ancillary protocol could run $1,500, $3,000 per year. Patients adding peptide protocols should budget an additional $1,800, $5,000 annually depending on compounds selected.

The table below summarizes approximate cost tiers for reference:

| Service Component | Low Estimate | High Estimate | |---|---|---| | Initial consultation | $250 | $350 | | Follow-up consultation (each) | $100 | $175 | | Lab panel (per draw) | $150 | $400 | | Testosterone cypionate (monthly) | $30 | $80 | | Ancillaries (AI, hCG) (monthly) | $40 | $120 | | Peptide protocol (monthly) | $150 | $400 |

Defy Medical vs. Alternatives: How Does It Compare?

The TRT telehealth market has expanded considerably since 2012. Comparing Defy Medical to its competitors requires looking at formulary breadth, clinical depth, cost, and the degree of individualization.

Defy Medical vs. Subscription TRT Startups (Hims, Roman, Maximus)

Direct-to-consumer startups like Hims, Roman, and Maximus typically offer a narrow formulary: one or two testosterone formulations, limited or no peptide access, and algorithmic or minimally supervised dosing adjustments. Their pricing can appear lower upfront ($100, $200/month all-in), but they often lack the clinical depth to manage complex cases, estrogen management, or fertility preservation protocols.

Defy Medical charges more but offers physician-level protocol customization, access to ancillaries like hCG and anastrozole, and peptide prescribing that subscription startups do not provide. For patients whose primary goal is simple testosterone replacement, a subscription service may be adequate. For patients with complex histories, fertility concerns, or interest in peptides, Defy's model is materially more comprehensive.

Defy Medical vs. Local Endocrinologists

Insurance-covered endocrinology provides the benefit of peer-reviewed, guideline-concordant care, but the formulary restrictions are significant. The Endocrine Society's 2018 Guideline states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness," and requires two morning serum testosterone measurements below threshold before initiating therapy. This conservative approach protects patients but excludes symptomatic men in the low-normal range.

Defy Medical treats a broader population, which means both that it serves patients who may genuinely benefit and that it may treat patients who do not have clinical hypogonadism by guideline standards. Patients should weigh this distinction carefully.

Defy Medical vs. Concierge-Style Competitors (Vitality, Evolve Telemed, MaxLife)

Several other cash-pay hormone practices offer similar models. Defy Medical's distinguishing features are its founding date (2012, giving it more clinical history), its public-facing educational content (podcasts, blog posts), and its formulary breadth in the peptide category. Pricing across these competitors is roughly comparable. Patient experience varies by individual provider within any practice, and online reviews reflect this variance.

Clinical Evidence Underlying Defy Medical's Core Services

Assessing legitimacy requires asking whether the treatments prescribed are supported by evidence, not just whether the practice holds the right licenses.

TRT Evidence Base

TRT for hypogonadal men has a substantial evidence base. Beyond the T Trials, a 2023 Cochrane review of testosterone therapy in men with hypogonadism found improvements in sexual function and bone mineral density, with the authors noting: "Testosterone probably improves sexual function outcomes compared with placebo." The review found no statistically significant increased cardiovascular risk in the trials analyzed, though longer-term data remain limited.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism did not significantly increase the rate of major adverse cardiovascular events vs. Placebo over a mean follow-up of 33 months (incidence 7.0% vs. 7.3%, P<0.001 for noninferiority). This trial substantially reduced the cardiovascular signal that had previously created prescribing hesitancy.

Peptide Evidence Base

The evidence for peptides is more variable. Sermorelin has the strongest human data among the GHRH analogs: a study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that sermorelin acetate increased mean IGF-1 levels and improved sleep quality in older adults. BPC-157 and TB-500 remain largely in preclinical stages; their use represents off-label prescribing of compounds with limited human safety data, which patients should factor into their decision.

Weight Management

For GLP-1 prescribing, Defy Medical operates in the same evidence space as other telehealth GLP-1 providers. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight reduction at 68 weeks vs. 2.4% for placebo. Access to this evidence-supported treatment through a cash-pay provider does not differ clinically from access through a primary care physician.

Patient Experience: What Reviews Reveal

Online reviews for Defy Medical on platforms like Google and Trustpilot skew positive, with recurring themes in both positive and negative feedback that are worth noting:

Positive Patterns in Patient Feedback

• Patients report detailed initial consultations compared to rushed primary care visits.
• Protocol individualization, including hCG co-prescribing and sensitive estradiol assays, is frequently mentioned as a differentiator.
• Patients with prior negative experiences at subscription startups often report better outcomes at Defy due to more nuanced lab interpretation.

Negative Patterns in Patient Feedback

• Wait times for initial appointments have been a recurring complaint, particularly during periods of high demand.
• Some patients report difficulty reaching providers for follow-up questions between scheduled consultations.
• The cumulative cost of labs, consultations, and medications surprises some patients who did not fully account for all components upfront.

Neither positive nor negative review patterns substitute for a patient's individual clinical assessment. What works well for one patient's protocol may not transfer to another's physiology.

Key Considerations Before Choosing Defy Medical

Before scheduling a consultation, prospective patients should think through several practical questions.

Are You a Candidate for the Services Offered?

TRT is FDA-approved for classical hypogonadism, defined by the Endocrine Society as a total testosterone <264 ng/dL with signs and symptoms of deficiency. Patients with borderline labs who are symptomatic occupy a clinically gray zone. Defy Medical will evaluate and potentially treat this population; a local endocrinologist may decline to do so. Neither approach is inherently wrong, but patients should understand which category they fall into.

State Availability and Telemedicine Rules

Telehealth prescribing of Schedule III controlled substances requires providers to hold licensure in the patient's state. Verify that Defy Medical providers are licensed in your state before scheduling. The DEA's Ryan Haight Online Pharmacy Consumer Protection Act and subsequent COVID-era telemedicine flexibilities have created a complex legal framework; confirm current rules at the time of your inquiry.

Insurance Reimbursement Is Not Available

No portion of Defy Medical's services is typically covered by insurance. Patients with high-deductible plans who have met their deductible may find that a local endocrinologist offering insurance-covered TRT is less expensive overall, even if the formulary is narrower.